28 Oct 2016 07:00
For immediate release | 28 October 2016 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Appointment of Deputy CEO
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that in addition to his role as Chief Commercial Officer, Peter Butterfield, an executive Director of the Company, is appointed Deputy CEO with immediate effect.
Peter joined Alliance's Board in February 2010 when he transferred to Alliance as part of the Company's acquisition of Cambridge Laboratories.
John Dawson, Alliance Pharma's Chief Executive, said: "Over the past six years it has been a pleasure working alongside Peter. He has made a substantial contribution to the development of the Company and to the senior leadership team. I am delighted with this appointment and I am sure he will excel in this new role as Deputy CEO."
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
Sarah Robinson, Company Secretary | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)